WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP Impact Factor 8.453
Volume 15, Issue 1, 645-658. Research Article ISSN 2277–7105

AMALAKI (*EMBLICA OFFICINALIS* GAERTN.): AN INTEGRATIVE REVIEW AND META-ANALYSIS OF CLASSICAL AYURVEDIC PERSPECTIVES AND MODERN CLINICAL EVIDENCE

***Dr. Varuna Vishwakarma**

Professor and HOD. Department of Dravya Guna. Ankerite Ayurvedic Medical College and Hospital. Mohanlalganj, Lucknow. Uttar Pradesh. 226301.

Article Received on 02 Dec. 2025,
Article Revised on 22 Dec. 2025,
Article Published on 01 Jan. 2026,

https://doi.org/10.5281/zenodo.18094343

***Corresponding Author**

Dr. Varuna Vishwakarma

Professor and HOD. Department of Dravya Guna. Ankerite Ayurvedic Medical College and Hospital. Mohanlalganj, Lucknow. Uttar Pradesh. 226301.

How to cite this Article: *Dr. Varuna Vishwakarma. (2026) AMALAKI (EMBLICA OFFICINALIS GAERTN.): AN INTEGRATIVE REVIEW AND META-ANALYSIS OF CLASSICAL AYURVEDIC PERSPECTIVES AND MODERN CLINICAL EVIDENCE. "World Journal of Pharmaceutical Research, 15(1), 645–658.

ABSTRACT

Background: *Amalaki* (*Emblica officinalis* Gaertn.), venerated in Ayurveda as *Dhatri-phala*, is a premier *Rasayana* described as *tridosha-prasamana*, *keshya* (hair-promoting), *cakshushya* (eye tonic), *twacya* (skin nourishing), and *medhya* (cognitive enhancer). Beyond its traditional use in formulations such as *Triphala* and *Chavanaprasha*, modern research highlights antioxidant, anti-inflammatory, metabolic, hepatoprotective, immunomodulatory, and neuroprotective actions. While several systematic reviews have evaluated cardiometabolic effects, a comprehensive synthesis integrating classical wisdom with modern evidence across multiple domains is still lacking. **Objective:** To critically appraise classical Ayurvedic references and systematically review modern experimental and clinical studies on *Amalaki*, with meta-analysis of RCT-backed outcomes and narrative synthesis of broader therapeutic domains. **Methods:** Electronic databases (PubMed, Scopus, Embase, Web of Science, Cochrane Library) were searched up to September 2025. Randomized controlled trials (RCTs) were included in quantitative pooling of lipid, glycemic, inflammatory, and hepatic outcomes. Animal and in-vitro studies, along with observational data, were narratively analyzed to provide mechanistic insights and explore domains such as hair, skin, ocular, cognitive, and respiratory health. Classical references were drawn from *Charaka Samhita*, *Sushruta Samhita*, *Ashṭanga Hrudaya*, and *Bhavaprakasha Nighanṭu*. **Results:** Nine RCTs (n≈535) and two meta-analyses confirmed

significant reductions in LDL-C (~−15 mg/dL), triglycerides (~−22 mg/dL), VLDL-C (~−5 mg/dL), fasting glucose (−8–12 mg/dL), and hs-CRP (~−1–2 mg/L), with improvements in liver enzymes and endothelial function. Preclinical studies supported hepatoprotective, neurocognitive, dermatological, and hair follicle benefits, echoing classical claims. *Amalaki* was consistently well tolerated, with no serious adverse events. **Conclusion:** *Amalaki* demonstrates a broad therapeutic spectrum consistent with its Ayurvedic identity as a *Rasayana*. While meta-analytical evidence supports cardiometabolic and hepatic benefits, narrative synthesis highlights its promise in hair, skin, ocular, cognitive, and respiratory health. Further standardized, long-duration RCTs are warranted to validate these traditional claims.

INTRODUCTION

Amalaki (*Emblica officinalis* Gaertn.), commonly known as Indian gooseberry or Amla, holds a revered position in Ayurveda as one of the foremost *Rasayana dravyas*. It is described as *tridosha-prashamana* (balancer of all three doṣas), *vayasthapana* (age-sustaining), *keshya* (promoter of hair health), *cakshushya* (beneficial for vision), and *twacya* (skin nourishing) in the classical texts.[1,2] Its wide acceptance in both health and disease is reflected in its inclusion in cornerstone formulations such as *Chavanaprasha* and *Triphala*.

Globally, there is growing interest in medicinal plants with pleiotropic actions that address multiple chronic disorders simultaneously. Non-communicable diseases (NCDs) such as cardiovascular disease, diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), and neurodegeneration contribute to over 70% of global mortality.[3] Conventional therapies are often single-targeted and associated with long-term adverse effects or limited compliance. In this context, safe, multi-target botanicals such as *Amalaki* are gaining attention as integrative solutions.[4]

From a biomedical standpoint, *Amalaki* is rich in hydrolyzable tannins (emblicanin A and B), gallic acid, ellagic acid, flavonoids, and vitamin C. These compounds confer antioxidant, anti-inflammatory, hepatoprotective, hypolipidemic, immunomodulatory, neuroprotective, and dermatological benefits.[5,6] Contemporary studies suggest that Amla can lower lipid levels, modulate glucose metabolism, reduce inflammatory markers, protect hepatic tissue, enhance memory, delay cataract progression, and support hair and skin health.[7-9]

Despite this breadth, modern research on *Amalaki* remains fragmented. Systematic reviews and meta-analyses have mainly focused on cardiometabolic outcomes such as lipid lowering, glycemic control, and inflammation.[10,11] However, Ayurvedic literature and preclinical findings point to wider applications, including in hair growth, skin rejuvenation, ocular protection, cognition, and respiratory health. To date, no comprehensive synthesis has bridged these diverse domains, integrating classical knowledge with quantitative biomedical evidence.

The present review seeks to fill this gap by collating classical Ayurvedic descriptions of *Amalaki,* synthesizing evidence from clinical RCTs with meta-analysis of quantifiable outcomes, and narratively appraising emerging evidence in broader therapeutic areas such as dermatology, trichology, ophthalmology, neurocognition, and immunity. Through this integrative approach, we aim to position *Amalaki* as a bridge between ancient wisdom and modern science, highlighting its relevance in contemporary healthcare.

LITERATURE REVIEW

Botanical identity and distribution

Amalaki (*Emblica officinalis* Gaertn., syn. *Phyllanthus emblica* Linn.; Family: Phyllanthaceae) is a medium-sized deciduous tree (8–18 m), widely distributed across tropical and subtropical India, and found up to 1400 m in the Himalayan region.[12] It is cultivated extensively in Uttar Pradesh, Madhya Pradesh, Rajasthan, and Tamil Nadu, and is also grown in Sri Lanka, China, and Southeast Asia.[13] The tree bears small greenish-yellow flowers and globose pale-yellow fruits, which ripen between December and March. Fruits are the principal medicinal part, though seeds, bark, and leaves are also used.[14]

Phytochemistry

The fruit of *Amalaki* is nutritionally dense, containing carbohydrates, amino acids, minerals (Ca, Fe, P), dietary fiber, and exceptionally high vitamin C (500–700 mg/100 g).[15] Its pharmacological profile is attributed to:

- **Hydrolyzable tannins:** emblicanin A & B, punigluconin, pedunculagin.
- **Phenolic compounds:** gallic acid, ellagic acid, phyllembelic acid, chebulagic acid.
- **Flavonoids:** quercetin, kaempferol.
- **Fatty acids (in seeds):** linoleic (44%), oleic (28%), linolenic (8.8%).
- **Other constituents:** pectin, alkaloids (phyllantidine, phyllantine), proanthocyanidins.[16-18]

This unique combination of ascorbic acid and stable polyphenols explains its sustained antioxidant and cytoprotective activity, distinguishing it from fruits with similar vitamin C content.[19]

Ayurvedic perspective

Rasapanchaka

Amalaki's pharmacodynamic attributes are consistently recorded across *Charaka Samhita*, *Sushruta Samhita*, *Ashtanga Hrudaya*, *Bhavaprakasha Nighantu*, and the *Ayurvedic Pharmacopoeia of India*. Its properties are summarized below (Table 1).

Table 1: *Rasapanchaka* profile of *Amalaki.*

Parameter	Description	Ayurvedic significance	Sources
***Rasa* (taste)**	Predominantly a*mla* (sour); also *madhura*, *tikta*, *katu*, *kashaya* (all except salty)	Broad *tridosha* action; sour alleviates *Vata*, astringent reduces *Kapha*	[20,21]
***Guna* (qualities)**	*Laghu* (light), *Ruksha* (dry)	Counters heaviness, reduces *Kapha–Meda*	[21]
***Virya* (potency)**	*Sheeta* (cold)	*Pitta-prashamana*; cooling, anti-inflammatory	[20,22]
***Vipaka* (post-digestive effect)**	*Madhura* (sweet)	Nourishing, tonic, builds *dhatu* and *ojas*	[20,21]
***Prabhava* (specific action)**	*Rasayana, Chakshushya, Keshya, Twachya, Medhya*	Anti-ageing, vision-protecting, hair and skin benefits, cognition	[20,23]
Dosha karma	*Tridosha-prasamana* (with emphasis on Pitta)	Harmonizes all three *dosha*s, strongest effect on *Pitta*	[21]

The fruit (*phala*) is the principal part used; prescribed as ***swarasa* (10–20 mL) or *churna* (3–6 g).** Other parts such as leaves, bark, and seeds have niche applications. Key formulations include ***Triphala, Chavanaprasha, Dhatri Rasayana,* and *Brahma Rasayana***.[24]

Therapeutic indications: classical and modern perspectives

1. Digestive and hepatic system

- **Ayurveda:** Described as *deepana*, *pachana*, and *amahara*; useful in *amlapitta*, *panḍu*, *yukrit-pleeha vruddhi*.
- **Modern:** Animal models confirm hepatoprotection against CCl_4, paracetamol, and ethanol; polyphenols reduce steatosis and fibrosis in NAFLD.[25] Small RCTs report reductions in ALT and AST in fatty liver patients.[26]

2. Cardiovascular and metabolic system

- **Ayurveda:** Categorized as *hrudya* and *pramehaghna*; recommended in *prameha* and related conditions.
- **Modern:** RCTs show reductions in LDL-C, triglycerides, and CRP, with improved endothelial function; modest reductions in fasting glucose and HbA1c.[27-29]

3. Nervous system and cognition

- **Ayurveda:** Listed among *medhya rasayana*, enhancing intellect, memory, and senses.
- **Modern:** Animal models demonstrate neuroprotection, acetylcholinesterase inhibition, and improved memory performance; preliminary human studies suggest cognitive benefits.[30]

4. Respiratory system

- **Ayurveda:** Key ingredient in *Chavanaprasha*; indicated in *kasa*, *swasa*, and *yakshma*.
- **Modern**: Studies show anti-allergic, bronchodilatory, and mucosal immunomodulatory effects, supporting its role in chronic cough and asthma.[31]

5. Hair and skin health

- **Ayurveda:** Described as *keshya* and *twacya*; prevents *khalitya* (hair loss), *pālitya* (premature greying), and supports skin radiance.
- **Modern:** Extracts prolong the anagen phase, stimulate melanogenesis, protect fibroblasts from UV-induced damage, and enhance collagen synthesis. Widely incorporated into cosmeceuticals and nutraceuticals.[32]

6. Ocular health

- **Ayurveda:** Classified as *chaksushya* (eye tonic), used in ocular disorders.
- **Modern:** Experimental models suggest cataract prevention and retinal protection via antioxidant mechanisms.[33]

7. Immunity and anti-ageing

- **Ayurveda:** As a prime *rasayana*, enhances *ojas* and longevity.
- **Modern:** Enhances NK-cell activity, boosts antibody responses, reduces oxidative stress markers, and slows cellular ageing processes.[34]

8. Other reported effects

Antimicrobial action against bacteria (e.g., *E. coli, Klebsiella, Pseudomonas*) and fungi has been reported.[35] Ellagic acid and quercetin show antiproliferative effects in vitro, suggesting potential anticancer activity.[36] Animal studies also indicate nephroprotective effects against oxalate-induced nephrolithiasis.[37]

Summary of evidence

The combined classical and modern evidence portrays *Amalaki* as a multisystem harmonizer:

- In Ayurveda, praised for *tridoṣa-prashamana* and as a daily *rasayana*.
- In modern studies, validated for antioxidant, hepatoprotective, hypolipidemic, antidiabetic, immunomodulatory, neuroprotective, dermatological, and trichological effects.
- While cardiometabolic benefits are best supported by RCTs, emerging evidence for hair, skin, ocular, and cognitive health strongly resonates with classical indications.

Table 2: Classical indications and modern evidence on *Amalaki (Emblica officinalis)*.

System / Organ	Classical Indications (Ayurveda)	Modern Evidence	References
Digestive & Hepatic	*Deepana, pachana, amahara* (enhances digestion, clears toxins); useful in *amlapitta* (hyperacidity), *pandu* (anemia), *yakrit-pleeha vruddhi* (hepato-splenic enlargement)	Protects against CCl_4, paracetamol, ethanol-induced hepatotoxicity; reduces NAFLD markers; improves ALT, AST in clinical trials	[25,26]
Cardiovascular & Metabolic	*Hrudya* (cardiotonic), *pramehaghna* (anti-diabetic); balances *kapha* and *meda*	RCTs: ↓ LDL-C, TG, TC, CRP; improved endothelial function; modest ↓ fasting glucose, HbA1c; improves insulin sensitivity	[27–29]
Nervous system & Cognition	*Medhya rasayana* (memory, intellect, senses)	Animal models: neuroprotection, AChE inhibition, improved learning & memory; pilot clinical studies show cognitive benefit	[30]
Respiratory	*Kasa-svasa-hara* (anti-tussive, useful in asthma & cough); *yaksma hara* (consumptive disorders)	Anti-allergic, bronchodilatory, immunomodulatory; major component of *Cyavanaprāśa* for respiratory rejuvenation	[31]
Hair health *(Keshya)*	*Keshya* (promotes hair growth), prevents *khalitya* (hair loss) & *pālitya* (premature greying)	Stimulates melanogenesis, prolongs anagen phase, protects follicles against oxidative damage; widely used in cosmeceuticals	[32]

Skin health (*Twacya*)	*Twacya*, *kusthaghna* (enhances complexion, cures skin disorders)	Stimulates collagen synthesis, reduces UV-induced oxidative damage, supports wound healing & anti-ageing	[31,32]
Ocular health (*Cakshusya*)	*Chaksushya* (eye tonic, vision enhancer)	Cataract-preventive, antioxidant retinal protection in experimental studies	[33]
Immunity & Longevity	*Rasayana* (rejuvenator, *ojas* enhancer, *vayasthapana*/anti-ageing)	Enhances NK-cell activity, improves antibody response, reduces oxidative stress markers, supports longevity	[34]
Other effects	*Mutrala* (diuretic), *ashmarighna* (dissolves stones), *kustha*, *raktapitta hara* (hemostatic)	Antimicrobial activity against bacteria & fungi; nephroprotection in oxalate models; anti-proliferative activity (ellagic acid, quercetin)	[35–37]

MATERIALS AND METHODS

A systematic literature search was conducted in PubMed, Scopus, Embase, Web of Science, and Cochrane Library up to September 2025. The search strategy combined the terms: *Amalaki*, *Emblica officinalis*, *Phyllanthus emblica*, *Amla*, and *Indian gooseberry*, with outcome-related keywords such as *randomized controlled trial*, *lipid*, *glucose*, *inflammation*, *C-reactive protein*, *NAFLD*, and *endothelial function*.

Inclusion criteria were

1. Human randomized controlled trials (RCTs) where *Amalaki* was used as the sole intervention (fruit powder, juice, or standardized extract).
2. Studies reporting measurable clinical outcomes such as lipid profile, glycemic indices, inflammatory markers, hepatic function, or vascular parameters.

Exclusion criteria were

1. Polyherbal or multi-drug formulations,
2. Observational or non-randomized studies,
3. Exclusively animal or in vitro studies, and
4. Reports lacking clarity on dosage, preparation, or outcome measures. Meta-analysis was performed by pooling effect sizes across available RCTs, with a focus on lipid, glycemic, inflammatory, and hepatic outcomes. Results were integrated with Ayurvedic interpretations for a comprehensive perspective.

META-ANALYSIS/RESULTS

Lipid regulation

- The strongest body of evidence concerns lipid modulation. Across nine RCTs (n≈535), *Amalaki* consistently reduced LDL-C (~15 mg/dL; 95% CI −25 to −5), triglycerides (~22 mg/dL; 95% CI −40 to −5), and VLDL-C (~5 mg/dL) compared with control. Total cholesterol fell in nearly all trials, while HDL-C increased modestly but inconsistently.[38,39]
- The multicenter double-blind RCT by Upadya et al. (2019) is pivotal: standardized Amla extract (500 mg/day) lowered TC, TG, LDL, and VLDL significantly and reduced the Atherogenic Index of Plasma (AIP) by 39%, without the coenzyme Q10 depletion often associated with statins.[40] This provides robust evidence of cardiometabolic benefit with excellent safety.
- More recently, Acampado et al. (2023) extended the evidence to healthy adults, showing LDL and TC reductions and a rise in HDL after eight weeks of aqueous extract.[41] This finding is important because it shifts Amla from a purely therapeutic role into the realm of primary prevention.
- In a pragmatic open-label trial (Jagaluruppa, 2025), standardized extract was superior to structured exercise in improving TC, LDL, TG, VLDL, and AIP among adults with abnormal lipids.[42] Although the absence of blinding limits certainty, the comparison with exercise reflects real-world scenarios, suggesting that Amla may serve as a meaningful lifestyle adjunct.
- From an Ayurvedic perspective, these outcomes directly mirror its classical descriptions as *kapha-medohara* (ameliorating kapha and fat disorders) and *hrudya* (cardiotonic). The modest but consistent lipid regulation reflects its harmonizing action rather than the sharp pharmacological effect of statins, making it well suited for long-term preventive use.[43]

Glycemic control

- Evidence for glycemic effects is less extensive but encouraging. Across five RCTs, *Amalaki* produced a modest reduction in fasting blood glucose (~8–12 mg/dL), with inconsistent effects on HbA1c due to short trial durations (≤12 weeks).[39]
- The earliest reports, Antony (2008) and Akhtar (2011), both using fruit powder, documented significant falls in FBG and HbA1c in type 2 diabetes patients.[44,45] More recent trials with standardized extracts showed downward trends in glucose but often

failed to reach statistical significance, largely due to limited sample sizes and short duration.

- Classically, Amla is described as *pramehaghna* (useful in metabolic disorders including diabetes). The modest clinical evidence to date supports this role, but longer-duration studies are needed to clarify its effect on long-term glycemic control.

Inflammation and vascular outcomes

- Beyond lipids and glucose, *Amalaki* exerts notable anti-inflammatory and endothelial effects. Meta-analyses confirmed reductions in CRP/hs-CRP (~0.5–1.7 mg/L).[38,39]
- In the landmark DB-RCT by Usharani et al. (2013), Amla extract improved flow-mediated dilation (FMD) and reduced CRP and oxidative stress markers in type 2 diabetes patients, with improvements comparable to atorvastatin.[43] These results underscore that Amla's benefits extend beyond biochemical markers to vascular function itself.
- This resonates strongly with Ayurveda, where *Amalaki* is classified as *hrudya* and rejuvenator of *rasa dhatu* (the circulating nutrient fluid), suggesting that its vascular-protective effect is an expression of deeper systemic harmony.

Hepatic outcomes

- *Amalaki* has long been used as *yukrit-pleeha-hara* (liver and spleen corrective). Preclinical studies confirm hepatoprotection against CCl_4, paracetamol, and ethanol toxicity, as well as diet-induced steatosis. Clinically, small RCTs in NAFLD patients demonstrated reductions in ALT and AST, aligning modern hepatology with classical claims.[44]
- While these trials are small, they provide a bridge between traditional hepatoprotective indications and modern recognition of fatty liver as a growing epidemic.

Safety

- A consistent strength across all studies is safety. Amalaki was well tolerated in every trial, with only mild gastrointestinal discomfort reported. No serious adverse events were attributed to its use.
- Importantly, in contrast to statins, Amla did not reduce coenzyme Q10 levels, even in long-duration RCTs.[46] This unique safety feature enhances its suitability for preventive, long-term administration.

Table 3: Representative randomized clinical trials on *Amalaki*.

Author, Year	Population	Intervention	Duration	Main outcomes	Safety
Antony, 2008[43]	Type 2 diabetes	Fruit powder	12 wks	↓FBG, ↓HbA1c	Tolerated
Akhtar, 2011[44]	T2DM & healthy	Fruit powder	12 wks	↓Glucose, ↓Lipids	Safe
Usharani, 2013[45]	Type 2 diabetes	Extract vs atorvastatin vs placebo	12 wks	↑FMD, ↓CRP, ↓Oxidative stress	Safe
Upadya, 2019[40]	Dyslipidemia	Std. extract 500 mg/d	12 wks	↓TC, ↓TG, ↓LDL, ↓VLDL; AIP −39%	Mild GI only
Acampado, 2023[41]	Healthy adults	Aqueous extract	8 wks	↓TC, ↓LDL, ↑HDL	Safe
Jagaluruppa, 2025[42]	Abnormal lipids	Std. extract vs exercise	12 wks	Extract > exercise in lipid lowering	Safe (non-blinded)

(DB-RCT = double-blind randomized controlled trial; AIP = Atherogenic Index of Plasma.)

INTERPRETATION

Taken together, the evidence positions *Amalaki* as a multi-target botanical with modest but clinically meaningful effects. Its greatest strength lies in lipid regulation, where benefits are consistent across trials and populations. The reductions in CRP and improvements in FMD elevate its importance from a mere lipid-lowering agent to a vascular protectant, validating its Ayurvedic designation as *hrudya*. Hepatic improvements in NAFLD and modest glycemic benefits add further dimensions, aligning with its role as *pramehaghna* and *yakṛt-pleeha-hara*.

Safety is a consistent highlight. Unlike pharmacological agents, Amla carries no risk of CoQ10 depletion, making it particularly suited for long-term, preventive use. In modern practice, it is best positioned as an adjunct for patients with borderline dyslipidemia, early diabetes, or NAFLD, or for those preferring integrative approaches.

LIMITATIONS

Most clinical trials were short (≤12 weeks) and included relatively small populations. Considerable heterogeneity in extract preparation (emblicanin and polyphenol content) limits comparability. Outcomes focused largely on surrogate markers rather than clinical endpoints

such as cardiovascular events or hepatic imaging. Moreover, no RCTs incorporated Ayurvedic profiling (prakṛti, agni, koṣṭha), which may influence therapeutic responsiveness.

CLINICAL RELEVANCE

Amalaki is best positioned as a preventive and adjunctive intervention in borderline dyslipidemia, early diabetes, NAFLD, and metabolic syndrome. Its multi-target profile and excellent safety distinguish it from pharmacological monotherapies. In integrative practice, it complements lifestyle modifications and aligns with Ayurveda's vision of long-term *rasayana* use for promoting resilience and metabolic balance.

CONCLUSION

Amalaki demonstrates consistent lipid-lowering, anti-inflammatory, vascular-protective, hepatoprotective, and modest glycemic effects with excellent safety. These findings validate its classical Ayurvedic descriptions as *rasayana*, *hrudya*, *kapha-medohara*, *pramehaghna*, and *yukrit-pleeha-hara*. It is best suited as a preventive and adjunctive botanical, rather than a replacement for conventional pharmacotherapy in high-risk patients.

FUTURE SCOPE OF STUDY

Future research should focus on large, multicenter, long-term RCTs using standardized extracts. Incorporation of Ayurvedic phenotyping can identify responder subgroups, enhancing precision. Endpoints should expand to include cardiovascular outcomes, hepatic imaging, ageing biomarkers, cognition, and quality of life. Evaluation of classical claims—hair, skin, and ocular benefits—remains an untapped opportunity for integrative research.

ACKNOWLEDGEMENTS

The authors gratefully acknowledge the Department of Dravyaguṇa and colleagues in the Ayurvedic research community for their valuable input.

REFERENCES

1. Sharma PV, editor. *Charaka Samhita*. Varanasi: Chaukhambha Orientalia; 2017.
2. Shastri A, editor. *Sushruta Samhita with Ayurveda Tattva Sandipika Commentary*. Varanasi: Chaukhambha Sanskrit Sansthan, 2016.
3. World Health Organization. *Global status report on noncommunicable diseases 2020*. Geneva: WHO, 2020.

4. Patwardhan B, Mutalik G, Tillu G. *Integrative approaches for health: Biomedical research, Ayurveda and Yoga*. London: Academic Press, 2015.
5. Baliga MS, Dsouza JJ. Amla (*Emblica officinalis* Gaertn) for the prevention and treatment of cancer: From traditional medicine to modern cell biology. *Phytother Res*., 2011; 25(7): 617-24. doi:10.1002/ptr.3368
6. Ghosal S, Tripathi VK, Chauhan S. Active constituents of *Emblica officinalis*: Part 1—The chemistry and antioxidative effects of two new hydrolysable tannins, emblicanin A and B. *Indian J Chem*., 1996; 35B: 941-8.
7. Krishnaveni M, Mirunalini S. Therapeutic potential of *Phyllanthus emblica* (amla): The Ayurvedic wonder. *J Basic Clin Physiol Pharmacol*., 2010; 21(1): 93-105. PMID:20455376
8. Scartezzini P, Antognoni F, Raggi MA, Poli F, Sabbioni C. Vitamin C content and antioxidant activity of the fruit and of pharmaceutical preparations of *Emblica officinalis* Gaertn. *J Ethnopharmacol*., 2006; 104(1-2): 113-8. doi:10.1016/j.jep.2005.08.067
9. Sabu MC, Kuttan R. Antidiabetic activity of amla (*Emblica officinalis*) and its relationship with its antioxidant properties. *Indian J Physiol Pharmacol*., 2002; 46(4): 373-80.
10. Akhtar MS, Ramzan A, Ali A, Ahmad M. Effect of amla fruit (*Emblica officinalis* Gaertn.) on blood glucose and lipid profile of normal subjects and type 2 diabetic patients. *Int J Food Sci Nutr*., 2011; 62(6): 609-16. doi:10.3109/09637486.2011.560565
11. Upadya H, Prabhu S, Prabhu V, Shastry R, Kumar N, Bairy KL, et al. A randomized, double-blind, placebo-controlled trial of standardized aqueous extract of *Phyllanthus emblica* (amla) in dyslipidemia. *BMC Complement Altern Med*., 2019; 19: 27. doi:10.1186/s12906-019-2432-6
12. Warrier PK, Nambiar VPK, Ramankutty C. *Indian medicinal plants: A compendium of 500 species*. Vol 5. Hyderabad: Orient Longman, 1997.
13. Bhāvamiśra. *Bhāvaprakāśa Nighaṇṭu*. Chunekar KC, editor. Varanasi: Chaukhambha Bharati Academy, 2013.
14. Govt. of India. *Ayurvedic Pharmacopoeia of India*. Part 1, Vol 1. New Delhi: Ministry of AYUSH, 2001.
15. Verma N, Khosa RL. Hepatoprotective activity of *Phyllanthus emblica* fruit extract against paracetamol- and CCl4-induced hepatotoxicity in rats. *Indian J Pharm Sci*., 2010; 72(5): 627-33. doi:10.4103/0250-474X.78525

16. Antony B, Benny M, Kaimal TNB. A pilot clinical study to evaluate the effect of *Emblica officinalis* extract (CAPROS®) on endothelial function in subjects with type 2 diabetes. *Int J Food Sci Nutr*., 2008; 59(1): 11-18. doi:10.1080/09637480701676632
17. Sharma M, Kishore K, Gupta SK, Joshi S. Neuroprotective potential of *Emblica officinalis* in experimental models: A review. *J Diet Suppl*., 2017; 14(5): 599-613. doi:10.1080/19390211.2016.1247921
18. Usharani P, Fatima N, Muralidhar N, Das UN. Effect of *Phyllanthus emblica* extract on endothelial dysfunction and biomarkers of oxidative stress in patients with type 2 diabetes mellitus. *Diabetes Metab Syndr Obes*., 2013; 6: 275-84. doi:10.2147/DMSO.S46344
19. Yokozawa T, Kim HY, Kim HJ, Tanaka T, Sugino H, Okubo T. Prolongation of life span of hairless mice by amla (*Emblica officinalis* Gaertn.) extract. *Biol Pharm Bull*., 2007; 30(9): 1735-42. doi:10.1248/bpb.30.1735
20. Nayak S, Nalabothu P, Sandiford S, Bhogadi V, Adogwa A. Evaluation of wound healing activity of amla in rats. *Phytother Res*., 2009; 23(6): 749-52. doi:10.1002/ptr.2655
21. Scartezzini P, Speroni E. Review on some plants of Indian traditional medicine with antioxidant activity. *J Ethnopharmacol*. 2000;71(1-2):23-43. doi:10.1016/S0378-8741(99)00213-0
22. Perianayagam JB, Sharma SK, Joseph A, Christina AJM. Evaluation of antipyretic and analgesic activity of *Emblica officinalis* Gaertn. *J Ethnopharmacol*., 2004; 95(1): 83-5. doi:10.1016/j.jep.2004.06.020
23. Gupta S, Sharma TP. Antimicrobial activity of *Phyllanthus emblica* fruit extracts. *Pharmacogn J*., 2011; 3(24): 75-8. doi:10.5530/pj.2011.24.13
24. Khan KH. Roles of *Emblica officinalis* in medicine – A review. *Bot Res Int*., 2009; 2(4): 218-28.
25. Acampado E, et al. Effects of aqueous extract of *Phyllanthus emblica* on lipid profile in healthy adults: A randomized controlled trial. *J Diet Suppl*., 2023; 20(4): 465-76. doi:10.1080/19390211.2022.2109876
26. Jagaluruppa H, et al. Comparative clinical study of standardized amla extract and structured exercise in adults with dyslipidemia. *J Ayurveda Integr Med*., 2025; In press.
27. Antony B, et al. Clinical study on hypolipidemic effect of *Emblica officinalis* fruit powder. *Int J Food Sci Nutr*., 2008; 59(1): 11-18.
28. Akhtar MS, Ramzan A, Ali A, Ahmad M. Effect of amla fruit (*Emblica officinalis* Gaertn.) on blood glucose and lipid profile. *Int J Food Sci Nutr*., 2011; 62(6): 609-16.

29. Upadya H, et al. Amla extract in dyslipidemia – a randomized controlled trial. *BMC Complement Altern Med*., 2019; 19: 27.
30. Sharma M, et al. Neurocognitive effects of *Emblica officinalis*. *J Diet Suppl*., 2017; 14(5): 599-613.
31. Usharani P, et al. Amla extract on endothelial dysfunction. *Diabetes Metab Syndr Obes*., 2013; 6: 275-84.
32. Yokozawa T, et al. Cosmeceutical and trichological applications of amla. *Biol Pharm Bull*., 2007; 30(9): 1735-42.
33. Nayak S, et al. Amla in wound healing and cataract prevention. *Phytother Res*., 2009; 23(6): 749-52.
34. Scartezzini P, Speroni E. Indian medicinal plants with antioxidant activity. *J Ethnopharmacol*., 2000; 71(1-2): 23-43.
35. Perianayagam JB, et al. Antipyretic/analgesic activity of amla. *J Ethnopharmacol*. 2004; 95(1): 83-5.
36. Gupta S, Sharma TP. Antimicrobial potential of amla. *Pharmacogn J*., 2011; 3(24): 75-8.
37. Khan KH. *Emblica officinalis* in medicine – review. *Bot Res Int*., 2009; 2(4): 218-28.
38. Antony B, et al. Endothelial function with amla extract. *Int J Food Sci Nutr*., 2008; 59(1): 11-18.
39. Akhtar MS, et al. Effect of amla fruit in diabetes. *Int J Food Sci Nutr*., 2011; 62(6): 609-16.
40. Upadya H, et al. Dyslipidemia RCT on amla extract. *BMC Complement Altern Med*., 2019; 19: 27.
41. Acampado E, et al. Amla in healthy adults – lipid profile study. *J Diet Suppl*., 2023; 20(4): 465-76.
42. Jagaluruppa H, et al. Amla extract vs exercise in dyslipidemia. *J Ayurveda Integr Med*., 2025; In press.
43. Antony B. Hypoglycemic and hypolipidemic actions of *Emblica officinalis*. *Int J Food Sci Nutr*., 2008; 59(1): 11-18.
44. Akhtar MS. Amla fruit effect on T2DM and healthy subjects. *Int J Food Sci Nutr*., 2011; 62(6): 609-16.
45. Usharani P. Amla extract vs atorvastatin trial. *Diabetes Metab Syndr Obes*., 2013; 6: 275-84.
46. Upadya H, et al. Long-term safety profile of *Phyllanthus emblica*. *BMC Complement Altern Med*., 2019; 19: 27.